Core Insights - X4 Pharmaceuticals will report its financial results for Q1 2025 on May 1, 2025, and provide corporate updates [1] - A conference call and webcast will be held on the same day at 8:30 a.m. EDT for investors [2] Company Overview - X4 Pharmaceuticals focuses on developing innovative therapies for rare immune system diseases with significant unmet needs [3] - The company has developed mavorixafor, an orally available CXCR4 antagonist, currently marketed in the U.S. as XOLREMDI® [3] - X4 is conducting a global pivotal Phase 3 clinical trial (4WARD) for mavorixafor in patients with certain chronic neutropenic disorders [3]

When the reverse stock split becomes effective, every thirty (30) of the company's issued shares of Common Stock will be combined into one issued share of Common Stock, without any change to the par value per share. This will reduce the number of outstanding shares of Common Stock from approximately 173.6 million shares to approximately 5.8 million shares. BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the im ...